Fragile X Syndrome (FXS) is a genetic disease because of a CGG trinucleotide expansion, called full mutation (greater than 200 CGG repeats), in the fragile X mental retardation one gene locus Xq27.3. It leads to a hyper-methylated region in the gene promoter, hence, silencing it and decreasing the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation.&nbsp;
&nbsp;
The people with FXS are present with intellectual disability, autism, hyperactivity, long face, large or prominent ears, and macroorchidism at puberty and after that. Most of the young children with FXS will present with language delay, sensory hyperarousal, and anxiety.
&nbsp;
Fragile X Syndrome Epidemiological Segmentation&nbsp;
The Epidemiological Segmentation of Fragile X Syndrome in 7MM from 2017 to 2030 is segmented as:-&nbsp;
<ul>
<li>Total Diagnosed Prevalence of Fragile X Syndrome</li>
<li>Gender-specific Diagnosed Prevalence of Fragile X Syndrome</li>
<li>Age-specific Diagnosed Prevalence of Fragile X Syndrome</li>
</ul>
&nbsp;
Fragile X Syndrome Epidemiology&nbsp;
<ul>
<li>The total cases of Fragile X Syndrome in 7MM in 2017 was 117,962&nbsp;&nbsp;</li>
<li>The gender-specific prevalent cases of Fragile X Syndrome (FXS) in the US were 40,102 for Males, and whereas for Females, it was observed to be 27,552 in 2017&nbsp;&nbsp;</li>
</ul>
&nbsp;
<a style="color: #0066cc; background-color: transparent;" href="https://www.delveinsight.com/report-store/fragile-x-syndrome-fxs-market" target="_blank" rel="noopener noreferrer">Fragile X Syndrome Market</a>
The market size of FXS in 7MM in 2017 was USD 33.8 Million&nbsp;&nbsp;
&nbsp;
Fragile X Syndrome Market Drivers
<ul>
<li>Funding and cooperation of various organizations</li>
<li>Identifying potential targets by animal models</li>
<li>Development of novel therapies</li>
</ul>
&nbsp;
Fragile X Syndrome Market Barriers
<ul>
<li>Failure of Clinical Trials</li>
<li>Disease Burden</li>
</ul>
&nbsp;
Fragile X Syndrome Emerging Drugs
The emerging drugs of the Fragile X Syndrome market are&nbsp;
<ul>
<li>Zygel (Cannabidiol/ZYN002)</li>
<li>Acamprosate</li>
<li>BPN14770</li>
<li>OV101 (gaboxadol)</li>
<li>Trofinetide</li>
<li>Metadoxine (MG01CI)</li>
<li>Ganaxolone</li>
</ul>
And many others.&nbsp;&nbsp;
&nbsp;
Fragile X Syndrome Key Players
The key players in the Fragile X Syndrome market are
<ul>
<li>Zynerba Pharmaceuticals</li>
<li>Confluence Pharmaceuticals</li>
<li>Tetra Therapeutics</li>
<li>Ovid Therapeutics</li>
<li>Neuren Pharmaceuticals</li>
<li>Alcobra Ltd./Arcturus Therapeutics</li>
<li>Marinus Pharmaceuticals</li>
</ul>
And many others.&nbsp;

Fragile X Syndrome Market

Fragile X Syndrome Symptoms, Treatment, epidemiology, companies, drugs infographic is a short guide to understand the problem and market landscape.